GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fonar Corp (NAS:FONR) » Definitions » Net Cash per Share

Fonar (FONR) Net Cash per Share : $2.31 (As of Dec. 2023)


View and export this data going back to 1981. Start your Free Trial

What is Fonar Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Fonar's Net Cash per Share for the quarter that ended in Dec. 2023 was $2.31.

The historical rank and industry rank for Fonar's Net Cash per Share or its related term are showing as below:

FONR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.04   Med: 14.14   Max: 33.2
Current: 7.04

During the past 13 years, the highest Price-to-Net-Cash Ratio of Fonar was 33.20. The lowest was 7.04. And the median was 14.14.

FONR's Price-to-Net-Cash is ranked worse than
50.63% of 79 companies
in the Medical Diagnostics & Research industry
Industry Median: 7.05 vs FONR: 7.04

Fonar Net Cash per Share Historical Data

The historical data trend for Fonar's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fonar Net Cash per Share Chart

Fonar Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 -2.62 -0.99 -0.04 1.31

Fonar Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 1.13 1.31 1.74 2.31

Competitive Comparison of Fonar's Net Cash per Share

For the Diagnostics & Research subindustry, Fonar's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fonar's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fonar's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Fonar's Price-to-Net-Cash falls into.



Fonar Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Fonar's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(51.313-49.755--7.079)/6.57853
=1.31

Fonar's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(53.258-45.965--7.59)/6.45581
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fonar  (NAS:FONR) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Fonar Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Fonar's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fonar (FONR) Business Description

Traded in Other Exchanges
Address
110 Marcus Drive, Melville, NY, USA, 11747
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue. The company's areas of operations are principally in the United States. It also exports to the United Arab Emirates, England, and Germany.
Executives
Timothy Raymond Damadian director, officer: CEO, President & Treasurer 110 MARCUS DR., MELVILLE NY 11747
Luciano B Bonanni officer: Exec VP, COO & PFO 110 MARCUS DR., MELVILLE NY 11747
Raymond V Damadian director, officer: president 31 FAIRBANKS BLVD, WOODBURY NY 11797
Robert J Janoff director 32 OSAGE DRIVE, HUNTINGTON STATION NY 11746
Data Charles O director 347 LINCOLN AVENUE, BEAVER PA 15009
Claudette Chan director 145 WEST 86TH STREET, APT. 15B, NEW YORK NY 10024
David B Terry officer: Secretary BOX 1439, EAST QUOGUE NY 11942
Robert Djerejian director 303 EAST 57TH STREET, APT 16LA, NEW YORK NY 10022